Chemoradiotherapy for lung cancer: Current status and perspectives

International Journal of Clinical Oncology

Volumn 9, Issue 6, 2004, Pages 435-443

  Ohe, Yuichiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemoradiotherapy; Fractionation; Japan Clinical Oncology Group; Non small cell lung cancer; Small cell lung cancer; Target based drug

Indexed keywords

CISPLATIN; ETOPOSIDE; GEFITINIB; IRINOTECAN; MITOMYCIN; NAVELBINE; VINBLASTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; LUNG NEOPLASMS;

EID: 12444308291     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-004-0453-x     Document Type: Review

References (78)

1. Cancer statistics in Japan 2003: The Editorial Board of the Cancer Statistics in Japan (2003) Foundation for Promotion of Cancer Research, Tokyo
2. Yamamoto S, Yamaguchi N (1998) Cancer statistics digest; lung cancer mortality. Jpn J Clin Oncol 28:352
3. Ihde DC (1992) Chemotherapy of lung cancer. N Engl J Med 327:1434-1441
4. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
5. Ohe Y, Ishizuka N, Tamura T, et al. (2003) Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG 0003A). Cancer Sci 94:729-734
6. Fukuoka M, Furuse K, Saijo N, et al. (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861
7. Furuse K, Fukuoka M, Nishiwaki Y, et al. (1998) Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 16:2126-2132
8. Noda K, Nishiwaki Y, Kawahara M, et al. (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91
9. Takada M, Fukuoka M, Kawahara M, et al. (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060
10. Turrisi AT, Kim K, Blum R, et al. (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271
11. Rusch VW, Giroux DJ, Kraut MJ, et al. (2001) Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 121:472-483
12. Albain KS, Scott CB, Rusch VR, et al. (2003) Phase III comparison of concurrent chemotherapy plus radiotherapy (CR/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from Intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 22:621
13. Nagai K, Tsuchiya R, Mori T, et al. (2003) A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA 2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 125:254-260
14. Furuse K, Fukuoka M, Kawahara M, et al. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699
15. Curran WJ, Scott CB, Langer CL, et al. (2003) Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOC 9410. Proc Am Soc Clin Oncol 22:621
16. Ohe Y, Yamamoto S, Suzuki K, et al. (2001) Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 37:54-63
17. Ohe Y (2002) Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer. Panminerva Med 44:205-212
18. Roswit B, Patno ME, Rapp R, et al. (1968) The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 90:688-697
19. Perez CA, Bauer M, Edelstein S, et al. (1986) Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 12:539-547
20. Pritchard R, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125:723-729
21. Marino P, Preatoni A, Canton A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stage IIIa and IIIb non small cell lung cancer. A meta-analysis. Cancer 76:593-601
22. Kubota K, Furuse K, Kawahara M, et al. (1994) Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 12:1547-1552
23. Sculier JP, Paesmans M, Lafitte JJ, et al. (1999) A randomized phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. Ann Oncol 10:295-303
24. Rowinsky EK, Donehower RC. (1995) Paclitaxel (taxol). N Engl J Med 332:1004-1014
25. Gelmon K. (1994) The taxoids: paclitaxel and docetaxel. Lancet 344:1267-1272
26. Fukuoka M, Niitani H, Suzuki A, et al. (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20
27. Schiller JH, Harrington D, Belani CP, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
28. Rosell R, Gatzemeier U, Betticher DC, et al. (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539-1549
29. Fossella F, Pereira JR, von Pawel J, et al. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024
30. Le Chevalier T, Brisgand D, Douillard JY, et al. (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367
31. Kubota K, Watanabe K, Kunitoh H, et al. (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254-261
32. Yokoyama A, Kurita Y, Saijo N, et al. (1998) Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br JCancer 78:257-262
33. Yokes EE, Herndon JE, Crawford J, et al. (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 20:4191-4198
34. Masters GA, Haraf DJ, Hoffman PC, et al. (1998) Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 16:2157-2163
35. Sekine I, Noda K, Oshita F, et al. (2004) Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci 95:691-695
36. Pierre F, Maurice P, Gilles R, et al. (2001) A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemoradiotherapy in locally advanced non small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 20:312a
37. Zatloukal PV, Petruzelka L, Zemanova M, et al. (2002) Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study. Proc Am Soc Clin Oncol 21:290a
38. Perez CA, Stanley K, Rubin P, et al. (1980) Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 6:987-994
39. Perer CA, Pajak TF, Rubin P, et al. (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer 59:1874-1881
40. Cox JD, Azarnia N, Byhardt RW, et al. (1990) A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555
41. Sause WT, Scott C, Taylor S, et al. (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205
42. Sause W, Kolesar P, Taylor S, et al. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364
43. Schild SE, Stella PJ, Geyer SM, et al. (2002) Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:370-378
44. Tsuchiya S, Ohe Y, Sugiura T, et al. (2001) Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601). Jpn J Clin Oncol 31:488-494
45. Saunders MI, Dische S, Barrett A, et al. (1996) Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. Br J Cancer 73:1455-1462
46. Saunders M, Dische S, Barrett A, et al. (1997) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350:161-165
47. Saunders MI, Rojas A, Lyn BE, et al. (1998) Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 78:1323-1328
48. Mehta MP, Tannehill SP, Adak S, et al. (1998) Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 16:3518-3523
49. Koutaissoff S, Wellmann D, Coucke P, et al. (1999) Hyperfractionated accelerated radiotherapy (HART) for inoperable, nonmetastatic non-small cell lung carcinoma of the lung (NSCLC): results of a phase II study for patients ineligible for combination radiochemotherapy. Int J Radiat Oncol Biol Phys 45:1151-1156
50. Belani CP, Wang W, Johnson DH, et al. (2003) Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and B non-small cell lung cancer (NSCLC): phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Proc Am Soc Clin Oncol 22:622
51. Ishikura S, Ohe Y, Nihei K, et al. (2002) A pilot study of hyperfractionated accelerated radiation therapy (HART) following induction cisplatin and vinorelbine for stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:321a
52. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530
53. Trovo MG, Minatel E, Franchin G, et al. (1992) Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 24:11-15
54. Ball D, Bishop J, Smith J, et al. (1999) A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 52:129-136
55. Clamon G, Herndon J, Cooper R, et al. (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4-11
56. Jeremic B, Shibamoto Y, Acimovic L, et al. (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458
57. Jeremic B, Shibamoto Y, Acimovic L, et al. (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14:1065-1070
58. Vokes EE, Herndon JE, Kelley MJ, et al. (2004) Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 22:618s
59. Gandara DR, Chansky K, Albain KS, et al. (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010
60. Fukuoka M, Yano S, Giaccone G, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246
61. Kris MG, Natale RB, Herbst RS, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158
62. Perez-Soler R, Chachoua A, Hammond LA, et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247
63. Raben D, Helfrich BA, Chan D, et al. (2002) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29:37-46
64. Harari PM, Huang SM (2001) Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289
65. Magne N, Fischel JL, Dubreuil A, et al. (2002) Sequence-dependent effects of ZD1839 ("Iressa") in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86: 819-827
66. Williams KJ, Telfer BA, Stratford IJ, et al. (2002) ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86:1157-1161
67. Huang SM, Li J, Armstrong EA, Harari PM (2002) Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 ("Iressa"). Cancer Res 62:4300-4306
68. Mountain CF (1987) Staging of lung cancer: the new international system. Lung Cancer 3:4-11
69. Micke P, Faldum A, Metz T, et al. (2002) Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease? Lung Cancer 37:271-276
70. Pignon JP, Arriagada R, Ihde DC, et al. (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624
71. Murray N (1997) Treatment of small cell lung cancer: the state of the art. Lung Cancer 17(Suppl 1):S75-S89
72. Bonner JA, Sloan JA, Shanahan TG, et al. (1999) Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17:2681-2691
73. Schild SE, Bonner JA, Shanahan TG, et al. (2004) Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:943-951
74. Arriagada R, Le Chevalier T, Riviere A, et al. (2002) Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol 13:748-754
75. Laplanche A, Monnet I, Santos-Miranda JA, et al. (1998) Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Lung Cancer 21:193-201
76. Gregor A, Cull A, Stephens RJ, et al. (1997) Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 33:1752-1758
77. Auperin A, Arriagada R, Pignon JP, et al. (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484
78. Saka H, Shimokata K, Yoshida S, et al. (1997) Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): a phase II study of Japan Clinical Oncology Group (JCOG 9504). Proc Am Soc Clin Oncol 16:447a